<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>COLCRYS - colchicine tablet, film coated </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>These highlights do not include all the information needed to use colchicine safely and effectively. See full prescribing information for COLCRYS®. COLCRYS® (colchicine, USP) tablets for Oral use Initial U.S. Approval: 1961</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-1"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<p>COLCRYS (colchicine, USP) tablets are an alkaloid indicated for:</p>
<ul>
<li>Prophylaxis and Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span> in adults (<a href="#S1.1">1.1</a>).</li>
<li>Familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF) in adults and children 4 years or older (<a href="#S1.2">1.2</a>).</li>
</ul>
<p>COLCRYS is not an analgesic medication and should not be used to treat   <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from other causes.</p>
<p>
 
</p>
<p></p>
<p>COLCRYS<span class="Sup">®</span> (colchicine, USP) tablets are indicated for prophylaxis and the treatment of acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>. </p>
<p> </p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:  </span></p>
<p>COLCRYS is indicated for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>. </p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>COLCRYS tablets are indicated for treatment of acute <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> when taken at the first sign of a flare.</p>
<p>
 
</p>
<p></p>
<p>COLCRYS<span class="Sup">®</span> (colchicine, USP) tablets are indicated in adults and children 4 years or older for treatment of familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF).</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-2"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>The long term use of colchicine is established for FMF and the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> but the safety and efficacy of repeat treatment for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> has not been evaluated. The dosing regimens for COLCRYS are different for each indication and must be individualized.</p>
<p>The recommended dosage of COLCRYS depends on the patient's age, renal function, hepatic function, and use of co-administered drugs [<span class="Italics">see<a href="#S2.4"> Dose Modification for Co-administration of Interacting Drugs (2.4)</a></span>].</p>
<p>COLCRYS tablets are administered orally, without regard to meals.</p>
<p>COLCRYS is not an analgesic medication and should not be used to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from other causes.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>The recommended dosage of COLCRYS for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> for adults and adolescents older than 16 years of age is 0.6 mg once or twice daily. The maximum recommended dose for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> is 1.2 mg/day.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>The recommended dose of COLCRYS for treatment of a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> is 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Higher doses have not been found to be more effective. The maximum recommended dose for treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> is 1.8 mg over a 1 hour period.  COLCRYS may be administered for treatment of a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> during prophylaxis at doses not to exceed 1.2 mg (2 tablets) at the first sign of the flare followed by 0.6 mg (1 tablet) one hour later. Wait 12 hours and then resume the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dose. </p>
<p>
 
</p>
<p></p>
<p>The recommended dosage of COLCRYS for FMF in adults is 1.2 mg to 2.4 mg daily.</p>
<p>COLCRYS should be increased as needed to control disease and as tolerated in increments of 0.3 mg/day to a maximum recommended daily dose. If intolerable side effects develop, the dose should be decreased in increments of 0.3 mg/day. The total daily COLCRYS dose may be administered in one to two divided doses.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis and Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>COLCRYS is not recommended for pediatric use in prophylaxis or treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF:</span></p>
<p>The recommended dosage of COLCRYS for FMF in pediatric patients 4 years of age and older is based on age. The following daily doses may be given as a single or divided dose twice daily:</p>
<ul>
<li> Children 4 – 6 years:  0.3 mg to 1.8 mg daily</li>
<li> Children 6 – 12 years:  0.9 mg to 1.8 mg daily</li>
<li> Adolescents older than 12 years: 1.2 mg to 2.4 mg daily</li>
</ul>
<p>
 
</p>
<p></p>
<p><span class="Bold">Concomitant Therapy:</span></p>
<p>Co-administration of COLCRYS with drugs known to inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of colchicine-induced toxic effects (Table 1).  If patients are taking or have recently completed treatment with drugs listed in Table 1 within the prior 14 days, the dose adjustments are as shown on the table below [<span class="Italics">see<a href="#S7"> DRUG INTERACTIONS  (7)</a></span>].</p>
<a name="table1"></a><table width="100%">
<caption><span>Table 1 COLCRYS Dose Adjustment for Co-administration with Interacting Drugs if no Alternative Available<a href="#footnote-1">*</a></span></caption>
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="30%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<col align="left" span="1" valign="top" width="10%">
<tbody class="Headless">
<tr class="First"><th align="left" colspan="8">														Strong CYP3A4 Inhibitors<a href="#footnote-2">†</a>
</th></tr>
<tr>
<td align="left"><span class="Bold">Drug</span></td>
<td align="left"><span class="Bold">Noted or Anticipated Outcome</span></td>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">FMF</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose</span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
</tr>
<tr>
<td align="left">Atazanavir<br>Clarithromycin<br>Darunavir/<br>Ritonavir<a href="#footnote-3">‡</a><br>Indinavir<br>Itraconazole Ketoconazole<br>Lopinavir/<br>Ritonavir<a href="#footnote-3" class="Sup">3</a><br>Nefazodone<br>Nelfinavir<br>Ritonavir<br>Saquinavir Telithromycin<br>Tipranavir/<br>Ritonavir<a href="#footnote-3" class="Sup">3</a>
</td>
<td align="left">Significant increase in colchicine plasma levels<a href="#footnote-1" class="Sup">1</a>; fatal colchicine toxicity has been reported with clarithromycin, a strong CYP3A4 inhibitor.  Similarly, significant increase in colchicine plasma levels is anticipated with other strong CYP3A4 inhibitors.</td>
<td align="left">0.6 mg twice a day<br><br><br><br>0.6 mg once a day<br>
</td>
<td align="left">0.3 mg once a day<br><br><br><br>0.3 mg once every other day</td>
<td align="left">1.2 mg<br>(2 tablets)  followed by 0.6 mg<br>(1 tablet)<br>1 hour later. Dose to be repeated no earlier than<br>3 days.</td>
<td align="left">0.6 mg<br>(1 tablet) ×<br>1 dose, followed by 0.3 mg<br>(1/2 tablet)<br>1 hour later. Dose to be repeated no earlier than<br>3 days.</td>
<td align="left">Maximum daily dose of 1.2 – 2.4 mg</td>
<td align="left">Maximum daily dose of  0.6 mg (may be given as<br>0.3 mg twice a day)</td>
</tr>
<tr><td align="left"><span class="Bold">Moderate CYP3A4 Inhibitors </span></td></tr>
<tr>
<td align="left"><span class="Bold">Drug</span></td>
<td align="left"><span class="Bold">Noted or Anticipated Outcome</span></td>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">FMF</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose</span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose</span></td>
</tr>
<tr>
<td align="left">Amprenavir<a href="#footnote-3" class="Sup">3</a> Aprepitant<br>Diltiazem Erythromycin Fluconazole Fosamprenavir<a href="#footnote-3" class="Sup">3</a><br>(pro-drug of<br>Amprenavir)<br>Grapefruit Juice Verapamil</td>
<td align="left">Significant increase in colchicine plasma concentration is anticipated.  Neuromuscular toxicity has been reported with diltiazem and verapamil interactions.</td>
<td align="left">0.6 mg twice a day<br><br><br><br><br>0.6 mg once a day<br>
</td>
<td align="left">0.3 mg twice a day or 0.6 mg once a day<br><br><br>0.3 mg once a day<br>
</td>
<td align="left">1.2 mg<br>(2 tablets)  followed by 0.6 mg<br>(1 tablet)<br>1 hour later. Dose to be repeated no earlier than<br>3 days.</td>
<td align="left">1.2 mg<br>(2 tablets) ×<br>1 dose. Dose to be repeated no earlier than<br>3 days.<br>
</td>
<td align="left">Maximum daily dose of 1.2 – 2.4 mg.</td>
<td align="left">Maximum daily dose of 1.2 mg (may be given as<br>0.6 mg twice a day)</td>
</tr>
<tr><td align="left"><span class="Bold">P-gp Inhibitors<a href="#footnote-2" class="Sup">2</a></span></td></tr>
<tr>
<td align="left"><span class="Bold">Drug</span></td>
<td align="left"><span class="Bold">Noted or Anticipated Outcome</span></td>
<td align="left"><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">FMF</span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
<td align="left"><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></span></td>
</tr>
<tr>
<td align="left"></td>
<td align="left"></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
<td align="left"><span class="Bold">Original Intended Dosage</span></td>
<td align="left"><span class="Bold">Adjusted Dose </span></td>
</tr>
<tr class="Last">
<td align="left">Cyclosporine Ranolazine</td>
<td align="left">Significant increase in colchicine plasma levels<a href="#footnote-1" class="Sup">1</a>; fatal colchicine toxicity has been reported with cyclosporine, a<br>P-gp inhibitor.  Similarly, significant increase in colchicine plasma levels is anticipated with other P-gp inhibitors.</td>
<td align="left">0.6 mg twice a day<br><br><br><br>0.6 mg once a day<br>
</td>
<td align="left">0.3 mg once a day<br><br><br><br>0.3 mg once every other day</td>
<td align="left">1.2 mg<br>(2 tablets)  followed by 0.6 mg<br>(1 tablet)<br>1 hour later. Dose to be repeated no earlier than<br>3 days.</td>
<td align="left">0.6 mg<br>(1 tablet) ×<br>1 dose. Dose to be repeated no earlier than<br>3 days.</td>
<td align="left">Maximum daily dose of 1.2 – 2.4 mg</td>
<td align="left">Maximum daily dose of  0.6 mg (may be given as<br>0.3 mg twice a day)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a></p>
<p><a name="footnote-reference-2" href="#footnote-2" class="Sup">2</a></p>
<p><a name="footnote-reference-3" href="#footnote-3" class="Sup">3</a></p>
<table width="100%">
<caption><span>Table 2 COLCRYS Dose Adjustment for Co-administration with Protease Inhibitors</span></caption>
<col align="left" span="1" valign="top" width="19%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="21%">
<col align="left" span="1" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Protease Inhibitor</th>
<th align="left" colspan="1">Clinical Comment</th>
<th align="left" colspan="2">w/Colchicine – Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></th>
<th align="left" colspan="1">w/Colchicine –<br>Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span></th>
<th align="left" colspan="1">w/Colchicine – Treatment of FMF</th>
</tr>
<tr>
<td align="left">Atazanavir sulfate<br>(Reyataz)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Reyataz.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Darunavir (Prezista)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Prezista/ritonavir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Fosamprenavir (Lexiva) with Ritonavir</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Lexiva/ritonavir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Fosamprenavir (Lexiva)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Lexiva/ritonavir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">1.2 mg (2 tablets) × 1 dose. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 1.2 mg (may be given as 0.6 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day</td>
<td align="left">0.3 mg twice a day or 0.6 mg once a day</td>
</tr>
<tr>
<td align="left">0.6 mg once a day</td>
<td align="left">0.3 mg once a day</td>
</tr>
<tr>
<td align="left">Indinavir (Crixivan)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Crixivan.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Lopinavir/Ritonavir (Kaletra)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Kaletra.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Nelfinavir mesylate (Viracept)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Viracept.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Ritonavir (Norvir)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Norvir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Saquinavir mesylate (Invirase)</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Invirase/ritonavir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr>
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
<tr>
<td align="left">Tipranavir (Aptivus)<br>
</td>
<td align="left">Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given colchicine with Aptivus/ritonavir.</td>
<td align="left"><span class="Bold">Original dose</span></td>
<td align="left"><span class="Bold">Adjusted dose</span></td>
<td align="left">0.6 mg (1 tablet) × 1 dose, followed by 0.3 mg (1/2 tablet) 1 hour later. Dose to be repeated no earlier than 3 days.</td>
<td align="left">Maximum daily dose of 0.6 mg (may be given as 0.3 mg twice a day)</td>
</tr>
<tr class="Last">
<td align="left">0.6 mg twice a day<br><br><br>0.6 mg once a day</td>
<td align="left">0.3 mg once a day<br><br><br>0.3 mg once every other day</td>
</tr>
</tbody>
</table>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> with COLCRYS is not recommended in patients receiving <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> dose of COLCRYS and CYP3A4 inhibitors.</p>
<p>
 
</p>
<p></p>
<p>Colchicine dosing must be individualized according to the patient's renal function [<span class="Italics">see<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>]. </p>
<p>Clcr in mL/minute may be estimated from serum creatinine (mg/dL) determination using the following formula:</p>
<table width="60%">
<col align="left" span="1" valign="middle" width="10%">
<col align="center" span="1" valign="middle" width="46%">
<col align="left" span="1" valign="middle" width="44%">
<tbody class="Headless">
<tr class="First">
<td align="left">Clcr =</td>
<td align="center">[140-age (years) × weight (kg)]</td>
<td align="left">  × 0.85 for female patients</td>
</tr>
<tr class="Last"><td align="left">72 × serum creatinine (mg/dL)</td></tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild (estimated creatinine clearance Clcr 50 – 80 mL/min) to moderate (Clcr 30 – 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring. For the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring [<span class="Italics">see<a href="#S12.3"> Clinical Pharmacology (12.3) </a>and<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild (Clcr 50 – 80 mL/min) to moderate (Clcr 30 – 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, a treatment course should be repeated no more than once every 2 weeks. For patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> requiring repeated courses consideration should be given to alternate therapy. For patients undergoing dialysis, the total recommended dose for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> should be reduced to a single dose of 0.6 mg (1 tablet).  For these patients, the treatment course should not be repeated more than once every 2 weeks [<span class="Italics">see<a href="#S12.3"> Clinical Pharmacology (12.3) </a>and<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>].</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> with COLCRYS is not recommended in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> who are receiving COLCRYS for prophylaxis.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF: </span></p>
<p>Caution should be taken in dosing patients with moderate and severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> and in patients undergoing dialysis. For these patients, the dosage should be reduced [<span class="Italics">see<a href="#S12.3"> Clinical Pharmacology (12.3)</a></span>]. Patients with mild (Clcr 50 – 80 mL/min) and moderate (Clcr 30 – 50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> should be monitored closely for adverse effects of COLCRYS. Dose reduction may be necessary. For patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (Clcr less than 30 mL/minute), start with 0.3 mg/day; any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine [<span class="Italics">see<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>].  For patients undergoing dialysis, the total recommended starting dose should be 0.3 mg (half tablet) per day.  Dosing can be increased with close monitoring.  Any increase in dose should be done with adequate monitoring of the patient for adverse effects of colchicine  [<span class="Italics">see<a href="#S12.3"> Clinical Pharmacology (12.3) </a>and<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span> </span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>: </span></p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine.  Dose reduction should be considered for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see<a href="#S8.7"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (8.7)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe impairment while the dose does not need to be adjusted, but a treatment course should be repeated no more than once every 2 weeks. For these patients, requiring repeated courses for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, consideration should be given to alternate therapy [<span class="Italics">see<a href="#S8.7"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (8.7)</a></span>].</p>
<p>Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> with COLCRYS is not recommended in patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> who are receiving COLCRYS for prophylaxis.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF:</span></p>
<p>Patients with mild to moderate <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should be monitored closely for adverse effects of colchicine. Dose reduction should be considered in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see<a href="#S8.7"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (8.7)</a></span>].</p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>For magnitude of effect on colchicine plasma concentrations [</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">2</a></dt>
<dd>Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given COLCRYS in conjunction with strong CYP3A4 or P-gp inhibitors [</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">3</a></dt>
<dd>When used in combination with Ritonavir, see dosing recommendations for strong CYP3A4 inhibitors [</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="section-3"></a><p></p>
<h1>DOSAGE FORMS &amp; STRENGTHS</h1>
<p class="First"></p>
<p>0.6 mg tablets — purple capsule-shaped, film-coated with AR 374 debossed on one side and scored on the other side.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p>Patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> should not be given COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir). In these patients, life-threatening and fatal colchicine toxicity has been reported with colchicine taken in therapeutic doses.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="section-5"></a><p></p>
<h1>WARNINGS AND PRECAUTIONS</h1>
<p class="First"></p>
<ul>
<li>
<span class="Italics">Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> </span>have been reported with colchicine in adults and children. Keep COLCRYS out of the reach of children (<a href="#S5.1">5.1</a>,<a href="#S10"> 10</a>).</li>
<li>
<span class="Italics"><span class="product-label-link" type="condition" conceptid="40528016" conceptname="Disorder of hematopoietic system">Blood dyscrasias</span>:</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported (<a href="#S5.2">5.2</a>).</li>
<li>Monitor for toxicity and if present consider temporary interruption or discontinuation of colchicine (<a href="#S5.2">5.2</a>,<a href="#S5.3"> 5.3</a>,<a href="#S5.4"> 5.4</a>,<a href="#S6"> 6</a>,<a href="#S10"> 10</a>).</li>
<li>
<span class="Italics">Drug interaction P-gp and/or CYP3A4 inhibitors: </span>Co-administration of colchicine with P-gp and/or strong CYP3A4 inhibitors has resulted in life-threatening interactions and <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> (<a href="#S5.3">5.3</a>,<a href="#S7"> 7</a>).</li>
<li>
<span class="Italics">Neuromuscular toxicity:</span> Myotoxicity including <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> may occur, especially in combination with other drugs known to cause this effect. Consider temporary interruption or discontinuation of COLCRYS (<a href="#S5.4">5.4</a>,<a href="#S7"> 7</a>).</li>
</ul>
<p>
 
</p>
<p></p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, both accidental and intentional, have been reported in adults and children who have ingested colchicine [<span class="Italics">see<a href="#S10"> OVERDOSAGE (10)</a></span>].  COLCRYS should be kept out of the reach of children.</p>
<p>
 
</p>
<p></p>
<p><span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">Myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, and <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span> have been reported with colchicine used in therapeutic doses.</p>
<p>
 
</p>
<p></p>
<p>Colchicine is a P-gp and CYP3A4 substrate. Life-threatening and fatal drug interactions have been reported in patients treated with colchicine given with P-gp and strong CYP3A4 inhibitors. If treatment with a P-gp or strong CYP3A4 inhibitor is required in patients with normal renal and hepatic function, the patient's dose of colchicine may need to be reduced or interrupted [<span class="Italics">see<a href="#S7"> DRUG INTERACTIONS (7)</a></span>].  Use of COLCRYS in conjunction with P-gp or strong CYP3A4 inhibitors (this includes all protease inhibitors, except fosamprenavir) is contraindicated in patients with renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see<a href="#S4"> CONTRAINDICATIONS (4)</a></span>]<span class="Italics">.</span></p>
<p>
 
</p>
<p></p>
<p>Colchicine-induced neuromuscular toxicity and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> have been reported with chronic treatment in therapeutic doses. Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk. Concomitant use of atorvastatin, simvastatin, pravastatin, fluvastatin, lovastatin, gemfibrozil, fenofibrate, fenofibric acid, or benzafibrate (themselves associated with myotoxicity) or cyclosporine with COLCRYS may potentiate the development of <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> [<span class="Italics">see<a href="#S7"> DRUG INTERACTIONS (7)</a></span>]. Once colchicine is stopped, the symptoms generally resolve within 1 week to several months.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-6"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>: </span>The most commonly reported adverse reaction in clinical trials for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span> The most common adverse reactions reported in the clinical trial for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (23%) and pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (3%).</p>
<p><span class="Bold">FMF: </span>Most common adverse reactions (up to 20%) are <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These effects are usually mild, transient, and reversible upon lowering the dose (<a href="#S6">6</a>).</p>
<p><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Mutual Pharmaceutical Company, Inc. at 1-888-351-3786 or drugsafety@urlpharma.com or FDA at 1-800-FDA-1088 or <span class="Italics">www.fda.gov/medwatch.</span></span></p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>The most commonly reported adverse reaction in clinical trials of colchicine for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> was <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>The most common adverse reactions reported in the clinical trial with COLCRYS for treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> were <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (23%) and pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (3%).</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF:</span></p>
<p>Gastrointestinal tract adverse effects are the most frequent side effects in patients initiating COLCRYS, usually presenting within 24 hours, and occurring in up to 20% of patients given therapeutic doses. Typical symptoms include cramping, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. These events should be viewed as dose-limiting if severe as they can herald the onset of more significant toxicity.</p>
<p>
 
</p>
<p></p>
<p>Because clinical studies are conducted under widely varying and controlled conditions, adverse reaction rates observed in clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug, and may not predict the rates observed in a broader patient population in clinical practice.</p>
<p>In a randomized, double-blind, placebo-controlled trial in patients with a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span>, gastrointestinal adverse reactions occurred in 26% of patients using the recommended dose (1.8 mg over 1 hour) of COLCRYS compared to 77% of patients taking a non-recommended high-dose (4.8 mg over 6 hours) of colchicine and 20% of patients taking placebo. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was the most commonly reported drug-related gastrointestinal adverse event. As shown in Table 3, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is associated with COLCRYS treatment. <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> was more likely to occur in patients taking the high-dose regimen than the low-dose regimen. Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurred in 19% and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> occurred in 17% of patients taking the non-recommended high-dose colchicine regimen but did not occur in the recommended low-dose COLCRYS regimen.</p>
<table width="100%">
<caption><span>Table 3 Number (%) of Patients with at Least One Drug-Related Treatment Emergent Adverse Events with an Incidence of ≥ 2% of Patients in Any Treatment Group</span></caption>
<col align="left" span="1" valign="top" width="60%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="10%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">MedDRA System Organ Class</th>
<th align="left" colspan="2">COLCRYS Dose</th>
<th align="left" colspan="1">Placebo</th>
</tr>
<tr>
<th align="left" colspan="1">MedDRA Preferred Term</th>
<th align="left" colspan="1">High (N=52)<br>n (%)</th>
<th align="left" colspan="1">Low (N=74)<br>n (%)</th>
<th align="left" colspan="1">(N=59)<br>n (%)</th>
</tr>
<tr>
<td align="left">Number of Patients with at Least One Drug-Related TEAE</td>
<td align="left">40 (77)</td>
<td align="left">27 (37)</td>
<td align="left">16 (27)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></td>
<td align="left">40 (77)</td>
<td align="left">19 (26)</td>
<td align="left">12 (20)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="left">40 (77)</td>
<td align="left">17 (23)</td>
<td align="left">8 (14)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="left">9 (17)</td>
<td align="left">3 (4)</td>
<td align="left">3 (5)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="left">9 (17)</td>
<td align="left">0</td>
<td align="left">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4183041" conceptname="Abdominal discomfort">Abdominal Discomfort</span></td>
<td align="left">0</td>
<td align="left">0</td>
<td align="left">2 (3)</td>
</tr>
<tr>
<td align="left">General Disorders and Administration Site Conditions</td>
<td align="left">4 (8)</td>
<td align="left">1 (1)</td>
<td align="left">1 (2)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="left">2 (4)</td>
<td align="left">1 (1)</td>
<td align="left">1 (2)</td>
</tr>
<tr>
<td align="left">Metabolic and Nutrition Disorders</td>
<td align="left">0</td>
<td align="left">3 (4)</td>
<td align="left">2 (3)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span></td>
<td align="left">0</td>
<td align="left">3 (4)</td>
<td align="left">1 (2)</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></td>
<td align="left">1 (2)</td>
<td align="left">1 (1.4)</td>
<td align="left">2 (3)</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td align="left">1 (2)</td>
<td align="left">1 (1)</td>
<td align="left">2 (3)</td>
</tr>
<tr>
<td align="left">Respiratory Thoracic <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></td>
<td align="left">1 (2)</td>
<td align="left">2 (3)</td>
<td align="left">0</td>
</tr>
<tr class="Last">
<td align="left">  Pharyngolaryngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span></td>
<td align="left">1 (2)</td>
<td align="left">2 (3)</td>
<td align="left">0</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>Serious toxic manifestations associated with colchicine include <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>, <span class="product-label-link" type="condition" conceptid="436093" conceptname="Disseminated intravascular coagulation">disseminated intravascular coagulation</span>, and injury to cells in the renal, hepatic, circulatory, and central nervous systems.</p>
<p>These most often occur with excessive accumulation or overdosage [<span class="Italics">see<a href="#S10"> OVERDOSAGE (10)</a></span>].</p>
<p>The following adverse reactions have been reported with colchicine. These have been generally reversible upon temporarily interrupting treatment or lowering the dose of colchicine.</p>
<p> </p>
<p><span class="Bold">Neurological:</span></p>
<p> sensory motor neuropathy   </p>
<p><span class="Bold">Dermatological: </span></p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>, <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rash</span>, <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>, rash   </p>
<p><span class="Bold">Digestive:</span></p>
<p> abdominal cramping, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4143342" conceptname="Lactose intolerance">lactose intolerance</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, vomiting   </p>
<p><span class="Bold">Hematological:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>, aplastic anemia   </p>
<p><span class="Bold">Hepatobiliary:</span></p>
<p> elevated AST, elevated ALT   </p>
<p><span class="Bold">Musculoskeletal:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>, elevated CPK, <span class="product-label-link" type="condition" conceptid="4142183" conceptname="Myotonia">myotonia</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, rhabdomyolysis   </p>
<p><span class="Bold">Reproductive:</span></p>
<p> <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span>, <span class="product-label-link" type="condition" conceptid="4339289" conceptname="Oligozoospermia">oligospermia</span></p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7"></a><p></p>
<h1>DRUG INTERACTIONS</h1>
<p class="First"></p>
<p>COLCRYS (colchicine) is a substrate of the efflux transporter P-glycoprotein (P-gp). Of the cytochrome P450 enzymes tested, CYP3A4 was mainly involved in the metabolism of colchicine. If COLCRYS is administered with drugs that inhibit P-gp, most of which also inhibit CYP3A4, increased concentrations of colchicine are likely. Fatal drug interactions have been reported.</p>
<p>Physicians should ensure that patients are suitable candidates for treatment with COLCRYS and remain alert for signs and symptoms of toxicities related to increased colchicine exposure as a result of a drug interaction. Signs and symptoms of COLCRYS toxicity should be evaluated promptly and, if toxicity is suspected, COLCRYS should be discontinued immediately.</p>
<p>Table 4 provides recommendations as a result of other potentially significant drug interactions.  Table 1 provides recommendations for strong and moderate CYP3A4 inhibitors and P-gp inhibitors.</p>
<table width="100%">
<caption><span>Table 4 Other Potentially Significant Drug Interactions</span></caption>
<col align="left" span="1" valign="top" width="40%">
<col align="left" span="1" valign="top" width="30%">
<col align="left" span="1" valign="top" width="30%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Concomitant Drug Class or Food</th>
<th align="left" colspan="1">Noted or anticipated Outcome</th>
<th align="left" colspan="1">Clinical Comment</th>
</tr>
<tr>
<td align="left">
<span class="Bold">HMG-Co A Reductase Inhibitors:</span><br>atorvastatin, fluvastatin, lovastatin, pravastatin, simvastatin</td>
<td align="left">Pharmacokinetic and/or <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacodynamic interaction</span>: the addition of one drug to a stable long-term regimen of the other has resulted in <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span> and <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> (including a fatality)</td>
<td align="left">Weigh the potential benefits and risks and carefully monitor patients for any signs or symptoms of <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span>, <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span>, or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, particularly during initial therapy; monitoring CPK (creatine phosphokinase) will not necessarily prevent the occurrence of severe <span class="product-label-link" type="condition" conceptid="137275" conceptname="Disorder of muscle">myopathy</span>.</td>
</tr>
<tr><td align="left">
<span class="Bold">Other Lipid Lowering Drugs</span>:  										<br>fibrates, gemfibrozil</td></tr>
<tr class="Last">
<td align="left">
<span class="Bold">Digitalis Glycosides:</span><br>digoxin</td>
<td align="left">P-gp substrate; <span class="product-label-link" type="condition" conceptid="4230337" conceptname="Rhabdomyolysis">rhabdomyolysis</span> has been reported</td>
</tr>
</tbody>
</table>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="section-8"></a><p></p>
<h1>USE IN SPECIFIC POPULATIONS</h1>
<p class="First"></p>
<ul>
<li>In the presence of mild to moderate renal or <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, adjustment of dosing is not required for treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span>, prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span>, and FMF but patients should be monitored closely (<a href="#S2.5">2.5</a>,<a href="#S8.6"> 8.6</a>).</li>
<li>In patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> the starting dose should be 0.3 mg/day, for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> no dose adjustment is required but a treatment course should be repeated no more than once every 2 weeks. In FMF patients, start with 0.3 mg/day and any increase in dose should be done with close monitoring (<a href="#S2.5">2.5</a>,<a href="#S8.6"> 8.6</a>).</li>
<li>In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, a dose reduction may be needed in prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> and FMF patients; while a dose reduction may not be needed in <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, a treatment course should be repeated no more than once every 2 weeks (<a href="#S2.5">2.5</a>,<a href="#S2.6"> 2.6</a>,<a href="#S8.6"> 8.6</a>,<a href="#S8.7"> 8.7</a>).</li>
<li>For patients undergoing dialysis, the total recommended dose for prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> should be 0.3 mg given twice a week with close monitoring. For treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, the total recommended dose should be reduced to 0.6 mg (1 tablet) × 1 dose and the treatment course should not be repeated more than once every two weeks.  For FMF patients the starting dose should be 0.3 mg per day and dosing can be increased with close monitoring (<a href="#S2.5">2.5</a>,<a href="#S8.6"> 8.6</a>).</li>
<li>Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus (<a href="#S8.1">8.1</a>).</li>
<li>Nursing Mothers: Caution should be exercised when administered to a nursing woman (<a href="#S8.3">8.3</a>).</li>
<li>Geriatric Use: The recommended dose of colchicine should be based on renal function (<a href="#S2.5">2.5</a>,<a href="#S8.5"> 8.5</a>).</li>
</ul>
<p>
 
</p>
<p></p>
<p>Pregnancy Category C</p>
<p>There are no adequate and well-controlled studies with colchicine in pregnant women. Colchicine crosses the human placenta. While not studied in the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, data from a limited number of published studies found no evidence of an increased risk of <span class="product-label-link" type="condition" conceptid="4067106" conceptname="Miscarriage">miscarriage</span>, <span class="product-label-link" type="condition" conceptid="443213" conceptname="Stillbirth">stillbirth</span>, or teratogenic effects among pregnant women using colchicine to treat familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF). Although animal reproductive and developmental studies were not conducted with COLCRYS, published animal reproduction and development studies indicate that colchicine causes embryofetal toxicity, <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, and altered postnatal development at exposures within or above the clinical therapeutic range. COLCRYS should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
<p>
 
</p>
<p></p>
<p>The effect of colchicine on labor and delivery is unknown.</p>
<p>
 
</p>
<p></p>
<p>Colchicine is excreted into human milk. Limited information suggests that exclusively breast-fed infants receive less than 10 percent of the maternal weight-adjusted dose. While there are no published reports of adverse effects in breast-feeding infants of mothers taking colchicine, colchicine can affect gastrointestinal cell renewal and permeability. Caution should be exercised and breast-feeding infants should be observed for adverse effects when COLCRYS is administered to a nursing woman.</p>
<p>
 
</p>
<p></p>
<p>The safety and efficacy of colchicine in children of all ages with FMF has been evaluated in uncontrolled studies. There does not appear to be an adverse effect on growth in children with FMF treated long-term with colchicine. <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout</span> is rare in pediatric patients, safety and effectiveness of colchicine in pediatric patients has not been established.</p>
<p>
 
</p>
<p></p>
<p>Clinical studies with colchicine for prophylaxis and treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> and for treatment of FMF did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients.  In general, dose selection for an elderly patient with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> should be cautious, reflecting the greater frequency of decreased renal function, concomitant disease, or other drug therapy [<span class="Italics">see<a href="#S2.4"> Dose Modification for Co-administration of Interacting Drugs (2.4)</a></span>].</p>
<p>
 
</p>
<p></p>
<p>Colchicine is significantly excreted in urine in healthy subjects. Clearance of colchicine is decreased in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Total body clearance of colchicine was reduced by 75% in patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> undergoing dialysis.</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild (estimated creatinine clearance Clcr 50 – 80 mL/min) to moderate (Clcr 30 – 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine. However, in patients with severe impairment, the starting dose should be 0.3 mg per day and any increase in dose should be done with close monitoring.  For the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients undergoing dialysis, the starting doses should be 0.3 mg given twice a week with close monitoring [<span class="Italics">see<a href="#S2.5"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (2.5)</a></span>]. </p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span></p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild (Clcr 50 – 80 mL/min) to moderate (Clcr 30 – 50 mL/min) renal function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, in patients with severe impairment, while the dose does not need to be adjusted for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, a treatment course should be repeated no more than once every 2 weeks. For patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> requiring repeated courses consideration should be given to alternate therapy.  For patients undergoing dialysis, the total recommended dose for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> should be reduced to a single dose of 0.6 mg (1 tablet).  For these patients, the treatment course should not be repeated more than once every 2 weeks [<span class="Italics">see<a href="#S2.5"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (2.5)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF</span></p>
<p>Although, pharmacokinetics of colchicine in patients with mild (Clcr 50 – 80 mL/min) and moderate (Clcr 30 – 50 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not known, these patients should be monitored closely for adverse effects of colchicine. Dose reduction may be necessary. In patients with severe <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> (Clcr less than 30 mL/minute) and end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis, COLCRYS may be started at the dose of 0.3 mg/day. Any increase in dose should be done with adequate monitoring of the patient for adverse effects of COLCRYS [<span class="Italics">see<a href="#S12.3"> Pharmacokinetics (12.3) </a>and<a href="#S2.5"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (2.5)</a></span>].</p>
<p>
 
</p>
<p></p>
<p>The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>, compared to healthy subjects [<span class="Italics">see<a href="#S12.3"> Pharmacokinetics (12.3)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>: </span></p>
<p>For prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild to moderate hepatic function impairment, adjustment of the recommended dose is not required, but patients should be monitored closely for adverse effects of colchicine.  Dose reduction should be considered for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> [<span class="Italics">see<a href="#S2.6"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (2.6)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">Treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>: </span></p>
<p>For treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with mild to moderate hepatic function impairment, adjustment of the recommended COLCRYS dose is not required, but patients should be monitored closely for adverse effects of COLCRYS. However, for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with severe impairment while the dose does not need to be adjusted, the treatment course should be repeated no more than once every 2 weeks. For these patients, requiring repeated courses for the treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>, consideration should be given to alternate therapy [<span class="Italics">see<a href="#S2.6"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (2.6)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Bold">FMF</span></p>
<p>In patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic disease</span>, dose reduction should be considered with careful monitoring [<span class="Italics">see<a href="#S12.3"> Pharmacokinetics (12.3) </a>and<a href="#S2.6"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (2.6)</a></span>].</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First"></p>
<p>Tolerance, abuse, or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> with colchicine has not been reported.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>The exact dose of colchicine that produces significant toxicity is unknown. Fatalities have occurred after ingestion of a dose as low as 7 mg over a 4-day period, while other patients have survived after ingesting more than 60 mg. A review of 150 patients who overdosed on colchicine found that those who ingested less than 0.5 mg/kg survived and tended to have milder toxicities, such as <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, whereas those who took 0.5 to 0.8 mg/kg had more severe reactions, such as <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">myelosuppression</span>. There was 100% mortality in those who ingested more than 0.8 mg/kg.</p>
<p>The first stage of acute colchicine toxicity typically begins within 24 hours of ingestion and includes <span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">gastrointestinal symptoms</span>, such as <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and significant <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">fluid loss</span>, leading to <span class="product-label-link" type="condition" conceptid="436375" conceptname="Hypovolemia">volume depletion</span>. Peripheral <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> may also be seen. Life-threatening complications occur during the second stage, which occurs 24 to 72 hours after drug administration, attributed to multi-organ failure and its consequences. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> is usually a result of <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span> and <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>. If the patient survives, recovery of multi-organ injury may be accompanied by rebound <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span> and <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span> starting about 1 week after the initial ingestion.</p>
<p>Treatment of colchicine <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">poisoning</span> should begin with gastric lavage and measures to prevent <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>. Otherwise, treatment is symptomatic and supportive. No specific antidote is known. Colchicine is not effectively removed by dialysis [<span class="Italics">see<a href="#S12.3"> Pharmacokinetics (12.3)</a></span>].</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-11"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Colchicine is an alkaloid chemically described as (S)N- (5,6,7,9-tetrahydro- 1,2,3, 10-tetramethoxy-9-oxobenzo [alpha] heptalen-7-yl) acetamide with a molecular formula of C<span class="Sub">22</span>H<span class="Sub">25</span>NO<span class="Sub">6</span> and a molecular weight of 399.4. The structural formula of colchicine is given below.</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a&amp;name=MM1.jpg"></p>
<p>Colchicine occurs as a <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">pale</span> yellow powder that is soluble in water. </p>
<p>COLCRYS<span class="Sup">®</span> (colchicine, USP) tablets are supplied for oral administration as purple, film-coated, capsule-shaped tablets (0.1575" × 0.3030"), debossed with 'AR 374' on one side and scored on the other, containing 0.6 mg of the active ingredient colchicine USP. Inactive ingredients: carnauba wax, FD&amp;C blue #2, FD&amp;C red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide, and triacetin.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-12"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>The mechanism by which COLCRYS exerts its beneficial effect in patients with FMF has not been fully elucidated; however, evidence suggests that colchicine may interfere with the intracellular assembly of the inflammasome complex present in <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> and monocytes that mediates activation of interleukin-1β. Additionally, colchicine disrupts cytoskeletal functions through inhibition of β-tubulin polymerization into microtubules, and consequently prevents the activation, degranulation, and migration of <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span> thought to mediate some <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> symptoms.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Absorption</span></p>
<p>In healthy adults, COLCRYS is absorbed when given orally, reaching a mean C<span class="Sub">max</span> of 2.5 ng/mL (range 1.1 to 4.4 ng/mL) in 1 to 2 hours (range 0.5 to 3 hours) after a single dose administered under fasting conditions. </p>
<p>Following oral administration of COLCRYS given as 1.8 mg colchicine over 1 hour to healthy, young adults under fasting conditions, colchicine appears to be readily absorbed, reaching mean maximum plasma concentrations of 6.2 ng/mL at a median 1.81 hours (range: 1.0 to 2.5 hours). Following administration of the non-recommended high-dose regimen (4.8 mg over 6 hours), mean maximal plasma concentrations were 6.8 ng/mL, at a median 4.47 hours (range: 3.1 to 7.5 hours).</p>
<p>After 10 days on a regimen of 0.6 mg twice daily, peak concentrations are 3.1 to 3.6 ng/mL (range 1.6 to 6.0 ng/mL), occurring 1.3 to 1.4 hours post-dose (range 0.5 to 3.0 hours).  Mean pharmacokinetic parameter values in healthy adults are shown in Table 5 below.</p>
<table width="90%">
<caption><span>Table 5 Mean (%CV) Pharmacokinetic Parameters in Healthy Adults Given COLCRYS</span></caption>
<col align="center" span="1" valign="bottom" width="35%">
<col align="center" span="1" valign="bottom" width="20%">
<col align="center" span="1" valign="bottom" width="15%">
<col align="center" span="1" valign="bottom" width="15%">
<col align="center" span="1" valign="bottom" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="1">C<span class="Sub">max</span> (colchicine ng/mL)</th>
<th align="center" colspan="1">T<span class="Sub">max</span><a href="#footnote-1">*</a> (h)</th>
<th align="center" colspan="1">Vd/F (L)</th>
<th align="center" colspan="1">CL/F (L/hr)</th>
<th align="center" colspan="1">t<span class="Sub">1/2</span> (h)</th>
</tr>
<tr><td align="center"><span class="Bold">COLCRYS 0.6 mg Single Dose (N=13)</span></td></tr>
<tr>
<td align="center">2.5 (28.7)</td>
<td align="center">1.5 (1.0 – 3.0)</td>
<td align="center">341.5 (54.4)</td>
<td align="center">54.1 (31.0)</td>
<td align="center">--</td>
</tr>
<tr><td align="center"><span class="Bold">COLCRYS 0.6 mg b.i.d. × 10 days (N=13)</span></td></tr>
<tr class="Last">
<td align="center">3.6 (23.7)</td>
<td align="center">1.3 (0.5 – 3.0)</td>
<td align="center">1150 (18.7)</td>
<td align="center">30.3 (19.0)</td>
<td align="center">26.6 (16.3)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-4" href="#footnote-4" class="Sup">4</a></p>
<p>In some subjects, secondary colchicine peaks are seen, occurring between 3 and 36 hours post-dose and ranging from 39% to 155% of the height of the initial peak. These observations are attributed to intestinal secretion and reabsorption and/or biliary recirculation. </p>
<p>Absolute bioavailability is reported to be approximately 45%.</p>
<p>Administration of COLCRYS with food has no effect on the rate of colchicine absorption, but did decrease the extent of colchicine by approximately 15%. This is without clinical significance.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Distribution</span></p>
<p>The mean apparent volume of distribution in healthy young volunteers was approximately 5 to 8 L/kg. </p>
<p>Colchicine binding to serum protein is low, 39 ± 5%, primarily to albumin regardless of concentration. </p>
<p>Colchicine crosses the placenta (plasma levels in the fetus are reported to be approximately 15% of the maternal concentration). Colchicine also distributes into breast milk at concentrations similar to those found in the maternal serum [<span class="Italics">see<a href="#S8.1"> Pregnancy (8.1) </a>and<a href="#S8.3"> Nursing Mothers (8.3)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Metabolism</span></p>
<p>Colchicine is demethylated to two primary metabolites, 2-O-demethylcolchicine and 3-O-demethylcolchicine (2- and 3-DMC, respectively), and one minor metabolite, 10-O-demethylcolchicine (also known as colchiceine).  <span class="Italics">In vitro</span> studies using human liver microsomes have shown that CYP3A4 is involved in the metabolism of colchicine to 2- and 3-DMC.  Plasma levels of these metabolites are minimal (less than 5% of parent drug). </p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Elimination/Excretion</span></p>
<p>In healthy volunteers (n=12) 40 – 65% of 1 mg orally administered colchicine was recovered unchanged in urine. Enterohepatic recirculation and biliary excretion are also postulated to play a role in colchicine elimination.  Following multiple oral doses (0.6 mg twice daily), the mean elimination half-lives in young healthy volunteers (mean age 25 to 28 years of age) is 26.6 to 31.2 hours. Colchicine is a substrate of P-gp.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Extracorporeal Elimination</span>: Colchicine is not removed by hemodialysis.</p>
<p>
 
</p>
<p></p>
<p><span class="Underline">Special Populations</span></p>
<p>There is no difference between men and women in the pharmacokinetic disposition of colchicine.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Pediatric Patients:</span> Pharmacokinetics of colchicine was not evaluated in pediatric patients.</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Elderly:</span> Pharmacokinetics of colchicine has not been determined in elderly patients. A published report described the pharmacokinetics of 1 mg oral colchicine tablet in four elderly women compared to six young healthy males. The mean age of the four elderly women was 83 years (range 75 – 93), mean weight was 47 kg (38 – 61 kg) and mean creatinine clearance was 46 mL/min (range 25 – 75 mL/min). Mean peak plasma levels and AUC of colchicine were two times higher in elderly subjects compared to young healthy males. However, it is possible that the higher exposure in the elderly subjects was due to decreased renal function. </p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>:</span> Pharmacokinetics of colchicine in patients with mild and moderate <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> is not known. A published report described the disposition of colchicine (1 mg) in young adult men and women with FMF who had normal renal function or end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> requiring dialysis. Patients with end-stage <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> had 75% lower colchicine clearance (0.17 <span class="Italics">vs</span> 0.73 L/hr/kg) and prolonged plasma elimination half-life (18.8 hrs <span class="Italics">vs</span> 4.4 hrs) as compared to subjects with FMF and normal renal function [<span class="Italics">see<a href="#S2.5"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (2.5) </a>and<a href="#S8.6"> <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span> (8.6)</a></span>].</p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic impairment</span>:</span> Published reports on the pharmacokinetics of IV colchicine in patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">chronic liver disease</span>, as well as those with alcoholic or <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, and normal renal function suggest wide inter-patient variability. In some subjects with mild to moderate cirrhosis, the clearance of colchicine is significantly reduced and plasma half-life prolonged compared to healthy subjects. In subjects with <span class="product-label-link" type="condition" conceptid="4135822" conceptname="Primary biliary cirrhosis">primary biliary cirrhosis</span>, no consistent trends were noted [<span class="Italics">see<a href="#S2.6"> Dose Modification in <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (2.6) </a>and<a href="#S8.7"> <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span> (8.7)</a></span>]. No pharmacokinetic data are available for patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh C).</p>
<p>
 
</p>
<p></p>
<p><span class="Italics">Drug interactions:</span></p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">In vitro</span></span><span class="Underline"> drug interactions: </span></p>
<p><span class="Italics">In vitro</span> studies in human liver microsomes have shown that colchicine is not an inhibitor or inducer of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4 activity. </p>
<p>
 
</p>
<p></p>
<p><span class="Italics"><span class="Underline">In vivo</span></span><span class="Underline"> drug interactions: </span></p>
<p>The effects of co-administration of other drugs with COLCRYS on C<span class="Sub">max</span>, AUC, and C<span class="Sub">min</span> are summarized in Table 6 (effect of other drugs on colchicine) and Table 7 (effect of colchicine on other drugs).  For information regarding clinical recommendations, see<a href="#table1"> Table 1 </a>in Dose Modification for Co-administration of Interacting Drugs [<span class="Italics">see<a href="#S2.4"> Dose Modification for Co-administration of Interacting Drugs (2.4)</a></span>].</p>
<table width="100%">
<caption><span>Table 6 Drug Interactions:  Pharmacokinetic Parameters for COLCRYS (colchicine, USP) tablets in the Presence of the Co-Administered Drug </span></caption>
<col align="left" span="1" valign="top" width="20%">
<col align="left" span="1" valign="top" width="20%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="5%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Co-administered Drug</th>
<th align="left" colspan="1">Dose of Co-administered Drug (mg)</th>
<th align="left" colspan="1">Dose of COLCRYS (mg)</th>
<th align="left" colspan="1">N</th>
<th align="center" colspan="2">% Change in Colchicine Concentrations from Baseline<br>(Range: Min - Max)</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">C<span class="Sub">max</span>
</th>
<th align="center" colspan="1">AUC<span class="Sub">0-t</span>
</th>
</tr>
<tr>
<td align="left">Cyclosporine</td>
<td align="left">100 mg<br>single-dose</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">23</td>
<td align="center">270.0<br>(62.0 to 606.9)</td>
<td align="center">259.0<br>(75.8 to 511.9)</td>
</tr>
<tr>
<td align="left">Clarithromycin</td>
<td align="left">250 mg BID,<br>7 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">23</td>
<td align="center">227.2<br>(65.7 to 591.1)</td>
<td align="center">281.5<br>(88.7 to 851.6)</td>
</tr>
<tr>
<td align="left">Ketoconazole</td>
<td align="left">200 mg BID,<br>5 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">24</td>
<td align="center">101.7<br>(19.6 to 219.0)</td>
<td align="center">212.2<br>(76.7 to 419.6)</td>
</tr>
<tr>
<td align="left">Ritonavir</td>
<td align="left">100 mg BID,<br>5 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">18</td>
<td align="center">184.4<br>(79.2 to 447.4)</td>
<td align="center">296.0<br>(53.8 to 924.4)</td>
</tr>
<tr>
<td align="left">Verapamil</td>
<td align="left">240 mg daily,<br>5 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">24</td>
<td align="center">40.1<br>(-47.1 to 149.5)</td>
<td align="center">103.3<br>(-9.8 to 217.2)</td>
</tr>
<tr>
<td align="left">Diltiazem</td>
<td align="left">240 mg daily,<br>7 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">20</td>
<td align="center">44.2<br>(-46.0 to 318.3)</td>
<td align="center">93.4<br>(-30.2 to 338.6)</td>
</tr>
<tr>
<td align="left">Azithromycin</td>
<td align="left">500 mg × 1 day, then<br>250 mg × 4 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">21</td>
<td align="center">21.6<br> (-41.7 to 222.0)</td>
<td align="center">57.1<br>(-24.3 to 241.1)</td>
</tr>
<tr class="Last">
<td align="left">Grapefruit Juice</td>
<td align="left">240 mL BID,<br>4 days</td>
<td align="left">0.6 mg<br>single-dose</td>
<td align="left">21</td>
<td align="center">-2.55<br>(-53.4 to 55.0)</td>
<td align="center">-2.36<br>(-46.4 to 62.2)</td>
</tr>
</tbody>
</table>
<p>Estrogen-containing oral contraceptives: In healthy female volunteers given ethinyl estradiol and norethindrone (Ortho-Novum<span class="Sup">®</span> 1/35) co-administered with COLCRYS (0.6 mg b.i.d. × 14 days), hormone concentrations are not affected.</p>
<p>In healthy volunteers given theophylline co-administered with COLCRYS (0.6 mg b.i.d. × 14 days), theophylline concentrations were not affected.</p>
<table width="100%">
<caption><span>Table 7 Drug Interactions:  Pharmacokinetic Parameters for Co-Administration of Drug in the Presence of COLCRYS (colchicine, USP) tablets</span></caption>
<col align="left" span="1" valign="top" width="30%">
<col align="center" span="1" valign="top" width="20%">
<col align="left" span="1" valign="top" width="15%">
<col align="left" span="1" valign="top" width="5%">
<col align="center" span="1" valign="top" width="15%">
<col align="center" span="1" valign="top" width="15%">
<tbody class="Headless">
<tr class="First">
<th align="left" colspan="1">Co-administered Drug</th>
<th align="center" colspan="1">Dose of Co-administered Drug (mg)</th>
<th align="left" colspan="1">Dose of COLCRYS (mg)</th>
<th align="left" colspan="1">N</th>
<th align="center" colspan="2">% Change in Co-Administered Drug Concentrations from Baseline<br>(Range: Min - Max)</th>
</tr>
<tr>
<th align="left" colspan="1"></th>
<th align="center" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="left" colspan="1"></th>
<th align="center" colspan="1">C<span class="Sub">max</span>
</th>
<th align="center" colspan="1">AUC<span class="Sub">0-t</span>
</th>
</tr>
<tr>
<td align="left">Theophylline</td>
<td align="center">300 mg (elixir) single-dose</td>
<td align="left">0.6 mg BID × 14 days</td>
<td align="left">27</td>
<td align="center">1.6<br>(-30.4 to 23.1)</td>
<td align="center">1.6<br>(-28.5 to 27.1)</td>
</tr>
<tr>
<td align="left">Ethinyl Estradiol (Ortho-Novum<span class="Sup">®</span> 1/35)</td>
<td align="center">21-Day Cycle (Active Treatment) + 7-Day Placebo</td>
<td align="left">0.6 mg BID × 14 days</td>
<td align="left">27<a href="#footnote-1">*</a>
</td>
<td align="center">-6.7<br>(-40.3 to 44.7)</td>
<td align="center">-3.0<a href="#footnote-2">†</a><br>(-25.3 to 24.9)</td>
</tr>
<tr class="Last">
<td align="left">Norethindrone (Ortho-Novum<span class="Sup">®</span> 1/35)</td>
<td align="center">0.94<br>(-37.3 to 59.4)</td>
<td align="left">-1.6<a href="#footnote-6" class="Sup">6</a><br>(-32.0 to 33.7)</td>
</tr>
</tbody>
</table>
<p><a name="footnote-reference-5" href="#footnote-5" class="Sup">5</a></p>
<p><a name="footnote-reference-6" href="#footnote-6" class="Sup">6</a></p>
<p>
 
</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">4</a></dt>
<dd>T</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">5</a></dt>
<dd>Conducted in healthy adult females</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">6</a></dt>
<dd>AUCτ</dd>
</dl>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="section-13"></a><p></p>
<h1>NONCLINICAL TOXICOLOGY</h1>
<p class="First"></p>
<p>Carcinogenesis</p>
<p>Carcinogenicity studies of colchicine have not been conducted. Due to the potential for colchicine to produce aneuploid cells (cells with an unequal number of chromosomes), there is theoretically an increased risk of malignancy.</p>
<p>
 
</p>
<p></p>
<p>Mutagenesis</p>
<p>Colchicine was negative for mutagenicity in the bacterial reverse mutation assay. In a chromosomal aberration assay in cultured human white blood cells, colchicine treatment resulted in the formation of micronuclei. Since published studies demonstrated that colchicine induces aneuploidy from the process of mitotic nondisjunction without structural DNA changes, colchicine is not considered clastogenic, although micronuclei are formed.</p>
<p>
 
</p>
<p></p>
<p>Impairment of Fertility</p>
<p>No studies of colchicine effects on fertility were conducted with COLCRYS. However, published nonclinical studies demonstrated that colchicine-induced disruption of microtubule formation affects meiosis and mitosis. Reproductive studies also reported abnormal sperm morphology and reduced sperm counts in males, and interference with sperm penetration, second meiotic division, and normal cleavage in females when exposed to colchicine. Colchicine administered to pregnant animals resulted in <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span> and <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>. These effects were dose dependent, with the timing of exposure critical for the effects on embryofetal development. The nonclinical doses evaluated were generally higher than an equivalent human therapeutic dose, but safety margins for reproductive and developmental toxicity could not be determined. </p>
<p>Case reports and epidemiology studies in human male subjects on colchicine therapy indicated that <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span> from colchicine is rare. A case report indicated that <span class="product-label-link" type="condition" conceptid="76744" conceptname="Azoospermia">azoospermia</span> was reversed when therapy was stopped. Case reports and epidemiology studies in female subjects on colchicine therapy have not established a clear relationship between colchicine use and <span class="product-label-link" type="condition" conceptid="197606" conceptname="Female infertility of tubal origin">female infertility</span>. However, since the progression of FMF without treatment may result in <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">infertility</span>, the use of colchicine needs to be weighed against the potential risks.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-14"></a><p></p>
<h1>CLINICAL STUDIES</h1>
<p class="First"></p>
<p>The evidence for the efficacy of colchicine in patients with chronic <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> is derived from the published literature.  Two randomized clinical trials assessed the efficacy of colchicine 0.6 mg twice a day for the prophylaxis of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in patients with <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> initiating treatment with urate lowering therapy. In both trials, treatment with colchicine decreased the frequency of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span>. </p>
<p>The efficacy of a low dosage regimen of oral colchicine (COLCRYS total dose 1.8 mg over 1 hour) for treatment of <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> was assessed in a multicenter, randomized, double-blind, placebo-controlled, parallel group, 1 week, dose comparison study. Patients meeting American College of Rheumatology criteria for <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout</span> were randomly assigned to three groups: high-dose colchicine (1.2 mg, then 0.6 mg hourly × 6 hours [4.8 mg total]); low-dose colchicine (1.2 mg, then 0.6 mg in 1 hour [1.8 mg total] followed by 5 placebo doses hourly); or placebo (2 capsules, then 1 capsule hourly × 6 hours). Patients took the first dose within 12 hours of the onset of the flare and recorded <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> intensity (11-point Likert scale) and adverse events over 72 hours. The efficacy of colchicine was measured based on response to treatment in the target joint, using patient self assessment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at 24 hours following the time of first dose as recorded in the diary. A responder was one who achieved at least a 50% reduction in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> score at the 24-hour post-dose assessment relative to the pre-treatment score and did not use rescue medication prior to the actual time of 24-hour post-dose assessment.</p>
<p>Rates of response were similar for the recommended low-dose treatment group (38%) and the non-recommended high-dose group (33%) but were higher as compared to the placebo group (16%) as shown in Table 8.</p>
<table width="100%">
<caption><span>Table 8 Number (%) of Responders Based on Target <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Joint Pain</span> Score at 24 Hours Post First Dose</span></caption>
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<col align="center" span="1" valign="top" width="20%">
<tbody class="Headless">
<tr class="First">
<th align="center" colspan="2">COLCRYS Dose Responders n (%)</th>
<th align="center" colspan="1">Placebo<br>n (%)<br>(n=58)</th>
<th align="center" colspan="2">% Differences in Proportion</th>
</tr>
<tr>
<th align="center" colspan="1">Low-dose<br>(n=74)</th>
<th align="center" colspan="1">High-dose<br>(n=52)</th>
<th align="center" colspan="1">Low-dose vs Placebo<br>(95% CI)</th>
<th align="center" colspan="1">High-dose vs Placebo<br>(95% CI)</th>
</tr>
<tr class="Last">
<td align="center">28 (38%)</td>
<td align="center">17 (33%)</td>
<td align="center">9 (16%)</td>
<td align="center">22 (8, 37)</td>
<td align="center">17 (1, 33)</td>
</tr>
</tbody>
</table>
<p>Figure 1 below shows the percentage of patients achieving varying degrees of improvement in <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> from baseline at 24 hours.</p>
<table width="100%">
<col align="center" span="1" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First"><td align="center"><span class="Bold">Figure 1<br><span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span> Relief on Low and High Doses of COLCRYS and Placebo (Cumulative)</span></td></tr>
<tr class="Last"><td align="center"><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a&amp;name=MM2.jpg"></td></tr>
</tbody>
</table>
<p>The evidence for the efficacy of colchicine in patients with FMF is derived from the published literature. Three randomized, placebo-controlled studies were identified. The three placebo-controlled studies randomized a total of 48 adult patients diagnosed with FMF and reported similar efficacy endpoints as well as inclusion and exclusion criteria.</p>
<p>One of the studies randomized 15 patients with FMF to a 6-month crossover study during which 5 patients discontinued due to study non-compliance. The 10 patients completing the study experienced 5 attacks over the course of 90 days while treated with colchicine compared to 59 attacks over the course of 90 days while treated with placebo. Similarly, the second study randomized 22 patients with FMF to a 4-month crossover study during which 9 patients discontinued due to lack of efficacy while receiving placebo or study non-compliance. The 13 patients completing the study experienced 18 attacks over the course of 60 days while treated with colchicine compared to 68 attacks over the course of 60 days while treated with placebo. The third study was discontinued after an interim analysis of 6 of the 11 patients enrolled had completed the study; results could not be confirmed.</p>
<p>Open-label experience with colchicine in adults and children with FMF is consistent with the randomized, controlled trial experience, and was utilized to support information on the safety profile of colchicine and for dosing recommendations. </p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-15"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>COLCRYS<span class="Sup">®</span> (colchicine, USP) tablets 0.6 mg, are purple, film-coated, capsule-shaped tablets, debossed with 'AR 374' on one side and scored on the other side.</p>
<table width="80%">
<col align="left" span="1" valign="middle" width="50%">
<col align="left" span="1" valign="middle" width="50%">
<tbody class="Headless">
<tr class="First">
<td align="left">Bottles of 30</td>
<td align="left">NDC 13310-119-07</td>
</tr>
<tr>
<td align="left">Bottles of 60</td>
<td align="left">NDC 13310-119-06</td>
</tr>
<tr>
<td align="left">Bottles of 100</td>
<td align="left">NDC 13310-119-01</td>
</tr>
<tr>
<td align="left">Bottles of 250</td>
<td align="left">NDC 13310-119-03</td>
</tr>
<tr>
<td align="left">Bottles of 500</td>
<td align="left">NDC 13310-119-05</td>
</tr>
<tr class="Last">
<td align="left">Bottles of 1000</td>
<td align="left">NDC 13310-119-10</td>
</tr>
</tbody>
</table>
<p>
 
</p>
<p></p>
<p>Store at 20° to 25°C (68° to 77°F).<br>[See USP Controlled Room Temperature]<br>Protect from light.</p>
<p>DISPENSE IN TIGHT, LIGHT-RESISTANT CONTAINER.</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-16"></a><p></p>
<h1>INFORMATION FOR PATIENTS</h1>
<p class="First"></p>
<p><span class="Italics">[See<a href="#MG"> Medication Guide</a>]</span></p>
<p>
 
</p>
<p></p>
<p>Patients should be advised to take COLCRYS as prescribed, even if they are feeling better. Patients should not alter the dose or discontinue treatment without consulting with their doctor. If a dose of COLCRYS is missed:</p>
<ul>
<li> For treatment of a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> when the patient is not being dosed for prophylaxis, take the missed dose as soon as possible.</li>
<li> For treatment of a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> during prophylaxis, take the missed dose immediately, wait twelve hours, then resume the previous dosing schedule. </li>
<li> For prophylaxis without treatment for a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span>, or FMF, take the dose as soon as possible and then return to the normal dosing schedule. However, if a dose is skipped the patient should not double the next dose.   </li>
</ul>
<p>
 
</p>
<p></p>
<p>Instruct patient that fatal <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span>, both accidental and intentional, have been reported in adults and children who have ingested colchicine. COLCRYS should be kept out of the reach of children.</p>
<p>
 
</p>
<p></p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">bone marrow depression</span> with <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>, <span class="product-label-link" type="condition" conceptid="137829" conceptname="Aplastic anemia">aplastic anemia</span>, and <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span> may occur with COLCRYS.</p>
<p>
 
</p>
<p></p>
<p>Patients should be advised that many drugs or other substances may interact with COLCRYS and some interactions could be fatal. Therefore, patients should report to their healthcare provider all of the current medications they are taking, and check with their healthcare provider before starting any new medications, particularly antibiotics. Patients should also be advised to report the use of non-prescription medication or herbal products. Grapefruit and grapefruit juice may also interact and should not be consumed during COLCRYS treatment.</p>
<p>
 
</p>
<p></p>
<p>Patients should be informed that <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">muscle pain</span> or <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> or <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> in fingers or toes may occur with COLCRYS alone or when it is used with certain other drugs. Patients developing any of these signs or symptoms must discontinue COLCRYS and seek medical evaluation immediately.</p>
<p>
 
</p>
<p></p>
<p>COLCRYS<span class="Sup">® </span>is a registered U.S. trademark of the URL Pharma, Inc. group of companies. © 2009 AR Holding Company, Inc., a URL Pharma, Inc. company<br>U.S. Patent Nos. 7,601,758; 7,619,004 and other patents pending</p>
<p>Manufactured for:<br>AR SCIENTIFIC, INC.<br>Philadelphia, PA 19124  USA<br>by:<br>MUTUAL PHARMACEUTICAL COMPANY, INC.<br>Philadelphia, PA 19124  USA</p>
<p>Rev 14, March 2012</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-17"></a><p></p>
<h1>SPL MEDGUIDE</h1>
<p class="First"></p>
<p><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">COLCRYS<br>(KOL-kris)</span></p>
<p><span class="Bold">(colchicine) tablets</span></p>
<p>Read the Medication Guide that comes with COLCRYS before you start taking it and each time you get a refill. There may be new information. This Medication Guide does not take the place of talking to your healthcare provider about your medical condition or treatment. You and your healthcare provider should talk about COLCRYS when you start taking it and at regular checkups.</p>
<p><a name="mostimportant"></a><span class="Bold">What is the most important information I should know about COLCRYS?</span></p>
<p>COLCRYS can cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> if levels of COLCRYS are too high in your body.</p>
<ul>
<li> Taking certain medicines with COLCRYS can cause your level of COLCRYS to be too high, especially if you have kidney or liver problems.</li>
<li> Tell your healthcare provider about all your medical conditions, including if you have kidney or liver problems. Your dose of COLCRYS may need to be changed.</li>
<li> Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements.</li>
<li> Even medicines that you take for a short period of time, such as antibiotics, can interact with COLCRYS and cause serious side effects or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</li>
<li> Talk to your healthcare provider or pharmacist before taking any new medicine.</li>
<li> Especially tell your healthcare provider if you take:</li>
</ul>
<table width="80%">
<col align="left" span="1" valign="top" width="5%">
<col align="left" span="1" valign="top" width="57%">
<col align="left" span="1" valign="top" width="38%">
<tbody class="Headless"><tr class="First Last">
<td align="left"> </td>
<td align="left"><ul>
<li>atazanavir sulfate (Reyataz<span class="Sup">®</span>)</li>
<li>cyclosporine (Neoral<span class="Sup">®</span>, Gengraf<span class="Sup">®</span>, Sandimmune<span class="Sup">®</span>)</li>
<li>fosamprenavir (Lexiva<span class="Sup">®</span>) with ritonavir</li>
<li>indinavir (Crixivan<span class="Sup">®</span>)</li>
<li>ketoconazole (Nizoral<span class="Sup">®</span>)</li>
<li>nefazodone (Serzone<span class="Sup">®</span>)</li>
<li>ritonavir (Norvir<span class="Sup">®</span>)</li>
<li>telithromycin (Ketek<span class="Sup">®</span>)</li>
</ul></td>
<td align="left"><ul>
<li>clarithromycin (Biaxin<span class="Sup">®</span>)</li>
<li>darunavir (Prezista<span class="Sup">®</span>)</li>
<li>fosamprenavir (Lexiva<span class="Sup">®</span>)</li>
<li>itraconazole (Sporanox<span class="Sup">®</span>)</li>
<li>lopinavir/ritonavir (Kaletra<span class="Sup">®</span>)</li>
<li>nelfinavir mesylate (Viracept<span class="Sup">®</span>)</li>
<li>saquinavir mesylate (Invirase<span class="Sup">®</span>)</li>
<li>tipranavir (Aptivus<span class="Sup">®</span>)</li>
</ul></td>
</tr></tbody>
</table>
<p>Ask your healthcare provider or pharmacist if you are not sure if you take any of the medicines listed above. This is not a complete list of all the medicines that can interact with COLCRYS.</p>
<ul>
<li> Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine.</li>
<li> Keep COLCRYS out of the reach of children.</li>
</ul>
<p><span class="Bold">What is COLCRYS?</span></p>
<p>COLCRYS is a prescription medicine used to:</p>
<ul>
<li>prevent and treat <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> in adults</li>
<li>treat familial Mediterranean <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> (FMF) in adults and children age four or older</li>
</ul>
<p>COLCRYS is not a <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> medicine and it should not be taken to treat <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> related to other conditions unless specifically prescribed for those conditions.</p>
<p><span class="Bold">Who should not take COLCRYS?</span></p>
<p>Do not take COLCRYS if you have liver or kidney problems and you take certain other medicines. Serious side effects, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, have been reported in these patients even when taken as directed. See "<a href="#mostimportant">What is the most important information I should know about COLCRYS</a>?"</p>
<p><span class="Bold">What should I tell my healthcare provider before starting COLCRYS?</span></p>
<p>See "<a href="#mostimportant">What is the most important information I should know about COLCRYS</a>?"</p>
<p>Before you take COLCRYS tell your healthcare provider about all your medical conditions including if you:</p>
<ul>
<li>have liver or kidney problems</li>
<li>are pregnant or plan to become pregnant. It is not known if COLCRYS will harm your unborn baby. Talk to your healthcare provider if you are pregnant or plan to become pregnant.</li>
<li>are breast-feeding or plan to breast-feed. COLCRYS passes into your breast milk. You and your healthcare provider should decide if you will take COLCRYS or breast-feed. If you take COLCRYS and breast-feed, you should talk to your child's healthcare provider about how to watch for side effects in your child.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including ones that you may only be taking for a short time, such as antibiotics. See "<a href="#mostimportant">What is the most important information I should know about COLCRYS</a>?" Do not start a new medicine without talking to your healthcare provider.</p>
<p>Using COLCRYS with certain other medicines, such as <span class="product-label-link" type="condition" conceptid="4224820" conceptname="Cholesterol">cholesterol</span>-lowering medications and digoxin, can affect each other causing serious side effects. Your healthcare provider may need to change your dose of COLCRYS. Talk to your healthcare provider about whether the medications you are taking might interact with COLCRYS, and what side effects to look for.</p>
<p><span class="Bold">How should I take COLCRYS?</span></p>
<ul>
<li>Take COLCRYS exactly as your healthcare provider tells you to take it. <span class="Bold">If you are not sure about your dosing</span>, call your healthcare provider.</li>
<li>COLCRYS can be taken with or without food.</li>
<li>If you take too much COLCRYS go to the nearest hospital emergency room right away.</li>
<li>Do not stop taking COLCRYS even if you start to feel better, unless your healthcare provider tells you.</li>
<li>Your healthcare provider may do blood tests while you take COLCRYS.</li>
<li>If you take COLCRYS daily and you miss a dose, then take it as soon as you remember. If it is almost time for your next dose, just skip the missed dose. Take the next dose at your regular time. Do not take 2 doses at the same time. </li>
<li>If you have a <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flare</span> while taking COLCRYS daily, report this to your healthcare provider.</li>
</ul>
<p><span class="Bold">What should I avoid while taking COLCRYS?</span></p>
<ul><li>Avoid eating grapefruit or drinking grapefruit juice while taking COLCRYS. It can increase your chances of getting serious side effects.</li></ul>
<p><span class="Bold">What are the possible side effects of COLCRYS?</span></p>
<p>COLCRYS can cause serious side effects or even cause <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. See "<a href="#mostimportant">What is the most important information I should know about COLCRYS</a>?"</p>
<p>Get medical help right away, if you have:</p>
<p> </p>
<ul>
<li><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></li>
<li><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Numbness</span> or <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> in   your fingers or toes</li>
<li>Unusual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> or   <span class="product-label-link" type="condition" conceptid="441737" conceptname="Contusion">bruising</span></li>
<li>Increased <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span></li>
<li>Feel weak or tired</li>
<li><span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pale</span> or gray color to your   lips, tongue, or palms of your hands</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> or   <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></li>
</ul>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">Gout Flares</span>:</span>  The most common side effect of COLCRYS in people who have <span class="product-label-link" type="condition" conceptid="440674" conceptname="Gout">gout flares</span> is <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>.</p>
<p><span class="Bold">FMF: </span> The most common side effects of COLCRYS in people who have FMF are <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p>Tell your healthcare provider if you have any side effect that bothers you or that does not go away.</p>
<p>These are not all of the possible side effects of COLCRYS. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p><span class="Bold">How should I store COLCRYS?</span></p>
<ul>
<li> Store COLCRYS at room temperature between 68° and 77°F (20° to 25°C).</li>
<li> Keep COLCRYS in a tightly closed container.</li>
<li> Keep COLCRYS out of the light.</li>
</ul>
<p><span class="Bold">Keep COLCRYS and all medicines out of the reach of children.</span></p>
<p><span class="Bold">General Information about COLCRYS</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use COLCRYS for a condition for which it was not prescribed. Do not give COLCRYS to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about COLCRYS. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about COLCRYS that is written for healthcare professionals.</p>
<p>For more information, go to www.COLCRYS.com or call 1-888-351-3786.</p>
<p><span class="Bold">What are the ingredients in COLCRYS?</span></p>
<p>Active Ingredient: Colchicine</p>
<p>Inactive Ingredients: carnauba wax, FD&amp;C blue #2, FD&amp;C red #40, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, pregelatinized starch, sodium starch glycolate, titanium dioxide, and triacetin.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>COLCRYS<span class="Sup">® </span>is a registered U.S. trademark of the URL Pharma, Inc. group of companies. © 2009 AR Holding Company, Inc., a URL Pharma, Inc. company<br>U.S. Patent Nos. 7,601,758; 7,619,004 and other patents pending</p>
<p>Manufactured for:<br>AR SCIENTIFIC, INC.<br>Philadelphia, PA 19124  USA<br>by:<br>MUTUAL PHARMACEUTICAL COMPANY, INC.</p>
<p>Rev 14, March 2012</p>
<p>
 
</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-18"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Colcrys </p>
<p><br></p>
<p>GENERIC: Colchicine</p>
<p><br></p>
<p>DOSAGE: TABLET, FILM COATED</p>
<p><br></p>
<p>ADMINSTRATION: ORAL</p>
<p><br></p>
<p>NDC: 52125-259-02</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>Colchicine 0.6mg in 1</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>carnauba wax</li>
<li>polyethylene glycols</li>
<li>starch, corn</li>
<li>polydextrose</li>
<li>sodium starch glycolate type A potato</li>
<li>titanium dioxide</li>
<li>cellulose, microcrystalline</li>
<li>FD&amp;C blue no. 2</li>
<li>FD&amp;C red no. 40</li>
<li>hypromelloses</li>
<li>lactose monohydrate</li>
<li>magnesium stearate</li>
<li>triacetin</li>
</ul>
<p><br></p>
<p>COLOR: purple</p>
<p><br></p>
<p>SHAPE: OVAL</p>
<p><br></p>
<p>SCORE: Two even pieces</p>
<p><br></p>
<p>SIZE: 8 mm</p>
<p><br></p>
<p>IMPRINT: AR;374</p>
<p><br></p>
<p>PACKAGING: 30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</p>
<p><br></p>
<p><br></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a&amp;name=MM3.jpg"></p>
<p><img alt="MM4" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a&amp;name=MM4.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>COLCRYS 		
					</strong><br><span class="contentTableReg">colchicine tablet, film coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-259(NDC:13310-119)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Colchicine</strong> (COLCHICINE) </td>
<td class="formItem">Colchicine</td>
<td class="formItem">0.6 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>starch, corn</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polydextrose</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue no. 2</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C red no. 40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triacetin</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">purple</td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (TABLET, FILM COATED) </td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">AR;374</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-259-02</td>
<td class="formItem">30  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA022352</td>
<td class="formItem">05/03/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 5/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>1ba766eb-5d6a-4b8f-9d5e-27429119c5ac</div>
<div>Set id: a0688f33-f00f-4a68-abc3-73ec887a471a</div>
<div>Version: 1</div>
<div>Effective Time: 20130503</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
